MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

Phase 3
Completed
Conditions
Pneumococcal Disease
Interventions
Biological: 20vPnC
First Posted Date
2020-11-24
Last Posted Date
2024-01-22
Lead Sponsor
Pfizer
Target Recruit Count
839
Registration Number
NCT04642079
Locations
🇺🇸

The Children's Clinic, Jonesboro, Arkansas, United States

🇺🇸

Clinical Research Prime, Idaho Falls, Idaho, United States

🇺🇸

Palmetto Pediatrics, PA, North Charleston, South Carolina, United States

and more 35 locations

A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia

Phase 2
Terminated
Conditions
Achondroplasia
Interventions
Biological: Recifercept
First Posted Date
2020-11-20
Last Posted Date
2024-02-15
Lead Sponsor
Pfizer
Target Recruit Count
60
Registration Number
NCT04638153
Locations
🇮🇹

Fondazione Policlinico Universitario Agostino - Gemelli IRCCS, Roma, Italy

🇺🇸

Nemours Alfred I duPont Hospital for Children, Wilmington, Delaware, United States

🇵🇹

Centro Hospitalar e Universitário de Coimbra - Hospital Pediátrico, Coimbra, Portugal

and more 11 locations

STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS

Phase 1
Completed
Conditions
Neoplasms
Interventions
First Posted Date
2020-11-19
Last Posted Date
2023-10-10
Lead Sponsor
Pfizer
Target Recruit Count
15
Registration Number
NCT04635631
Locations
🇨🇳

Jilin Cancer Hospital, Changchun, Jilin, China

🇨🇳

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

PHARMACOKINETIC CHARACTERIZATION OF PF-06651600 IN CHINESE ADULT PARTICIPANTS

Phase 1
Completed
Conditions
Healthy Participants
Interventions
First Posted Date
2020-11-18
Last Posted Date
2021-02-17
Lead Sponsor
Pfizer
Target Recruit Count
9
Registration Number
NCT04634565
Locations
🇨🇳

Peking University Third Hospital, Beijing, Beijing, China

🇨🇳

North District of Peking University Third Hospital, Beijing, China

A Study of Single Ascending Doses of PF-07258669 in Healthy Adult Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: PF-07258669
Drug: Placebo
First Posted Date
2020-11-16
Last Posted Date
2024-02-21
Lead Sponsor
Pfizer
Target Recruit Count
29
Registration Number
NCT04628793
Locations
🇺🇸

QPS-MRA, LLC-Main Office, South Miami, Florida, United States

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

Phase 1
Terminated
Conditions
Non-small-cell Lung Cancer
Urothelial Carcinoma
Colorectal Carcinoma
Ovarian Carcinoma
Squamous Cell Carcinoma of the Head and Neck
Renal Cell Carcinoma
Interventions
Biological: PF-07209960
First Posted Date
2020-11-16
Last Posted Date
2024-07-29
Lead Sponsor
Pfizer
Target Recruit Count
37
Registration Number
NCT04628780
Locations
🇺🇸

UCLA Hematology/Oncology, Los Angeles, California, United States

🇺🇸

Santa Monica UCLA Medical Center & Orthopaedic Hospital, Santa Monica, California, United States

🇺🇸

The University of Texas MD Anderson Cancer Center- Investigational Pharmacy, Houston, Texas, United States

and more 10 locations

Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections

Completed
Conditions
Gram Negative Infections
Interventions
Drug: Ceftazidime-avibactam
First Posted Date
2020-11-13
Last Posted Date
2024-08-14
Lead Sponsor
Pfizer
Target Recruit Count
189
Registration Number
NCT04628572
Locations
🇮🇳

Fortis Hospital, Bhandup West, India

🇮🇳

Metro Hospital, Noida, India

🇮🇳

Grant Medical Foundation Ruby Hall Clinic, Pune, India

and more 4 locations

Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: PF-07304814
First Posted Date
2020-11-13
Last Posted Date
2021-01-06
Lead Sponsor
Pfizer
Target Recruit Count
16
Registration Number
NCT04627532
Locations
🇺🇸

New Haven Clinical Research Unit, New Haven, Connecticut, United States

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

Phase 3
Recruiting
Conditions
Ulcerative Colitis
Interventions
First Posted Date
2020-11-10
Last Posted Date
2024-12-03
Lead Sponsor
Pfizer
Target Recruit Count
120
Registration Number
NCT04624230
Locations
🇺🇸

Center for Advanced Pediatrics, Atlanta, Georgia, United States

🇺🇸

Children's Healthcare of Atlanta - Arthur M. Blank Hospital, Atlanta, Georgia, United States

🇺🇸

Texas Children's Hospital, Houston, Texas, United States

and more 92 locations

Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity

Phase 1
Completed
Conditions
Obesity
Interventions
First Posted Date
2020-11-09
Last Posted Date
2023-12-01
Lead Sponsor
Pfizer
Target Recruit Count
16
Registration Number
NCT04621227
Locations
🇺🇸

Anaheim Clinical Trials, LLC, Anaheim, California, United States

© Copyright 2025. All Rights Reserved by MedPath